|
1
|
Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
|
Clin Infect Dis
|
2010
|
1.92
|
|
2
|
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
|
Diagn Microbiol Infect Dis
|
2008
|
1.33
|
|
3
|
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
|
Antimicrob Agents Chemother
|
2010
|
1.07
|
|
4
|
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
|
J Antimicrob Chemother
|
2008
|
1.06
|
|
5
|
Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.
|
BMC Infect Dis
|
2010
|
1.06
|
|
6
|
Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.
|
Antimicrob Agents Chemother
|
2011
|
0.88
|
|
7
|
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.
|
Respir Med
|
2006
|
0.81
|
|
8
|
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.
|
J Microbiol Immunol Infect
|
2011
|
0.77
|